NATIONAL UNIVERSITY OF SINGAPORE

Researchers at the National University of Singapore have developed Nanostraw Electro-actuated Transfection (NExT), a non-viral technology that efficiently delivers genetic material into immune cells with minimal disruption.

Singapore researchers have discovered that the ADAR1 gene inhibits response to lenalidomide in multiple myeloma patients by suppressing immune pathways critical for the drug's effectiveness.

KYAN Technologies' Optim.AI platform has shown 85.4% concordance with actual clinical responses across more than 20 cancer types, validating its effectiveness in predicting both treatment response and resistance.

A phase II trial in Singapore demonstrated that adding bevacizumab to pembrolizumab significantly improved response rates in platinum-resistant nasopharyngeal carcinoma patients, with 58.3% responding to combination therapy versus 12.5% with pembrolizumab alone.

A novel drug delivery system using red blood cell-derived nanoparticles targets mutant EGFR in non-small cell lung cancer (NSCLC).

A novel CD7 CAR-T cell therapy developed by NUHS has shown significant promise in treating relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL).

Researchers utilized the CURATE.AI platform to personalize treatment for Waldenström macroglobulinemia, a rare blood disorder, by dynamically adjusting dosages based on patient responses.

The National University of Singapore and Cerner Enviza have collaborated on Project Golden Years, investigating evolving attitudes towards dementia prevention in Singapore through real-world qualitative research.